Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients.
Over a 10-y period (1989-99) we prospectively evaluated all patients with fungaemia among 16,555 admissions (21,004 blood cultures) at a national cancer referral institution in the Slovak Republic. A prospective protocol was completed on 140 patients with fungaemia, which was then analysed in terms of aetiology, clinical characteristics, potential risk factors and outcome. The most frequently isolated organism was C. albicans, in 75 patients (52.9%), followed by non-albicans Candida spp. in 45 patients (32.1%). Non-Candida spp. yeasts represented 16 episodes in 16 patients (11.4%). Moulds caused 4 episodes in 4 patients (3.6% of all fungaemias) and all were caused by Fusarium spp. Mucositis (p = 0.025), > or = 3 positive blood cultures (p = 0.02), acute leukaemia (p = 0.00001), neutropenia (p = 0.0015), quinolone prophylaxis (p < 0.000005) and breakthrough fungaemia (p = 0.004) during prophylaxis with fluconazole (p = 0.03) and itraconazole (p = 0.005) were significantly more associated with non-Candida than C. albicans spp. Furthermore, attributable mortality was higher in the subgroup of non-Candida than C. albicans spp. (50.0 vs. 18.7%, p < 0.02). The only independent risk factor for inferior outcome was antifungal therapy of < 10 d duration (odds ratio 2.1, 95% confidence interval, p < 0.001). Aetiology, neutropenia and mucositis were not independent risk factors for higher mortality in multivariate analysis; however, they were risk factors for inferior outcome in univariate analysis (p < 0.05-0.005).
Kovacicová
G
G
Department of Pharmacology, School of Public Health, University of Trnava, Slovak Republic.
Spánik
S
S
Kunová
A
A
Trupl
J
J
Sabo
A
A
Koren
P
P
Sulcová
M
M
Mateicka
F
F
Novotný
J
J
Pichnová
E
E
Jurga
L
L
Chmelík
B
B
Obertik
T
T
West
D
D
Krcéry
V
V
D000293:Adolescent; D000935:Antifungal Agents / Q000627:therapeutic use*; D002406:Catheterization, Peripheral / Q000009:adverse effects; D016469:Fungemia / Q000188:drug therapy* / Q000382:microbiology* / Q000401:mortality / Q000517:prevention & control; D005658:Fungi / Q000145:classification / Q000302:isolation & purification*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D011446:Prospective Studies; D012307:Risk Factors; D016896:Treatment Outcome
D000935:Antifungal Agents